Glaukos iDose TR

2023

Start of sales

On December 14, 2023, medical technology company Glaukos announced the release of the iDose TR implant for the treatment of eye diseases. The solution on the market is focused primarily on patients suffering from open-angle glaucoma and ocular hypertension.

According to the World Health Organization (WHO), as of August 2023, at least 2.2 billion people suffer from near or far vision disorders worldwide. Moreover, at least 1 billion of them could have prevented or corrected the deterioration. One of the main reasons that provoke visual impairment among these 1 billion patients is glaucoma, a group of eye diseases characterized by a constant or periodic increase in intraocular pressure above the level acceptable for a given person. Therefore, therapy of such conditions is of great importance for maintaining visual acuity. In this case, the iDose TR implant is an alternative to conventional ophthalmic medicinal fluids.

Glaukos announces release of iDose TR implant for eye disease

The size of the article is approximately 200 times smaller than a conventional glaucoma drug drop. The implant is placed in a certain area of ​ ​ the eye, after which it begins to continuously release travoprost, a means that is used in ophthalmology to reduce intraocular pressure and prevent the progression of glaucoma.

iDose TR provides continuous treatment of high ocular pressure for up to three years. Thus, the risk that non-compliance with conventional therapy will affect outcomes is eliminated. The implant has received approval from the U.S. Food and Drug Administration (FDA). However, there is a limitation: as of the end of 2023, the product is intended for single injection into the eye.^[1]

Implant announcement

On April 5, 2023, Celanese International Chemical Corporation announced the conclusion of a cooperation agreement with Glaukos. The goal of the partnership is to increase the effectiveness of the treatment of glaucoma - eye diseases, characterized by a constant or periodic increase in intraocular pressure above an acceptable level.

As part of the collaboration, the Celanese VitalDose drug delivery platform will be used as a component of the new Glaukos iDose TR system: it is a microinvasive implant designed to reduce intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension. The iDose TR system is designed to maintain an optimal course of treatment and eliminate side effects that may occur with conventional therapy. The implant provides long-term treatment around the clock.

Glaukos iDose TR

As Celanese notes, its VitalDose platform serves to reliably release the drug in a controlled manner. This approach improves the effectiveness of the treatment of glaucoma, since patients do not need to worry about compliance with the dosages and prescriptions of the doctor. Celanese and Glaukos technologies will be able to help a huge number of people with eye disease around the world.

The inclusion of the VitalDose platform in Glaukos' iDose TR therapy contributes to our mission to improve the health of ophthalmic clinic patients living with chronic eye disease. Our team is pleased to support Glaukos in promoting the iDose TR system, which will help people in need of alternative glaucoma treatment, "said Cyonna Holmes, Head of Global Business Strategy at Celanese Ophthalmology.[2]

Notes